Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:
- Unique arrangement structures at specific product life cycle stages
- Protecting IP
- Avoiding short-term fallout
- The impact of collaboration on future growth and exit strategies
- Strategies from both sides of the agreement: increasing the opportunity for future collaborations
Panelist:
- Richard A. Kaufman, Partner, Foley & Lardner LLP
- David Webb, Vice President, Research & Site Director, Celgene
- David J. Weitz, Senior Vice President, General Counsel and Chief Intellectual Property Counsel, Takeda Pharmaceuticals
- Linda Pullan, Ph.D., Pullan Consulting
Related Insights
09 September 2024
Labor & Employment Law Perspectives
No More Chevron Deference: What Does This Mean for Employers?
From 1984 until June 2024, a reviewing court had to defer to a federal agency’s reasonable interpretation of ambiguous statutes, even if the court would have interpreted the statute differently.
09 September 2024
Labor & Employment Law Perspectives
Redefining Workplace Safety: OSHA’s Updated Hazard Communication Rule Explained
In May 2024, the Occupational Safety and Health Administration issued a final rule to amend the Hazard Communication Standard, aligning it more closely with the seventh revision of the United Nations’ Globally Harmonized System of Classification and Labeling of Chemicals.
09 September 2024
PharmaPatents